Establishment of Drug-resistant HBV Small-animal Models by Hydrodynamic Injection

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2015 Nov 19

PMID 26579395

Authors

Junjun Cheng

Yanxing Han

Jian-Dong Jiang

Affiliations

Soon will be listed here.

Abstract

In antiviral therapy of hepatitis B virus (HBV) infection, drug resistance remains a huge obstacle to the long-term effectiveness of nucleoside/tide analogs (NAs). Primary resistance mutation (rtM204V) contributes to lamivudine (LAM)-resistance, and compensatory mutations (rtL180M and rtV173L) restore viral fitness and increase replication efficiency. The evaluation of new anti-viral agents against drug-resistant HBV is limited by the lack of available small-animal models. We established LAM-resistance HBV replication mice models based on clinical LAM-resistant HBV mutants. Double (rtM204V+rtL180M) or triple (rtM204V+rtL180M+rtV173L) lamivudine-resistant mutations were introduced into HBV expression vector, followed by hydrodynamic injection into tail vein of NOD/SCID mice. Viremia was detected on days 5, 9, 13 and 17 and liver HBV DNA was detected on day 17 after injection. The serum and liver HBV DNA levels in LAM-resistant model carrying triple mutations are the highest among the models. Two NAs, LAM and entecavir (ETV), were used to test the availability of the models. LAM and ETV inhibited viral replication on wild-type model. LAM was no longer effective on LAM-resistant models, but ETV retains a strong activity. Therefore, these models can be used to evaluate anti-viral agents against lamivudine-resistance, affording new opportunities to establish other drug-resistant HBV small-animal models.

References

Erhardt A, Blondin D, Hauck K, Sagir A, Kohnle T, Heintges T . Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut. 2005; 54(7):1009-13. PMC: 1774609. DOI: 10.1136/gut.2004.060327. View

Lai C, Yuen M . Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. Hepatology. 2012; 57(1):399-408. DOI: 10.1002/hep.25937. View

Pollicino T, Saitta C, Raimondo G . Hepatocellular carcinoma: the point of view of the hepatitis B virus. Carcinogenesis. 2011; 32(8):1122-32. DOI: 10.1093/carcin/bgr108. View

Yant S, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay M . Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet. 2000; 25(1):35-41. DOI: 10.1038/75568. View

Goldstein S, Zhou F, Hadler S, Bell B, Mast E, Margolis H . A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005; 34(6):1329-39. DOI: 10.1093/ije/dyi206. View

Marion P, Oshiro L, Regnery D, Scullard G, ROBINSON W . A virus in Beechey ground squirrels that is related to hepatitis B virus of humans. Proc Natl Acad Sci U S A. 1980; 77(5):2941-5. PMC: 349522. DOI: 10.1073/pnas.77.5.2941. View

Ganem D, Prince A . Hepatitis B virus infection--natural history and clinical consequences. N Engl J Med. 2004; 350(11):1118-29. DOI: 10.1056/NEJMra031087. View

Yang P, Althage A, Chung J, Chisari F . Hydrodynamic injection of viral DNA: a mouse model of acute hepatitis B virus infection. Proc Natl Acad Sci U S A. 2002; 99(21):13825-30. PMC: 129782. DOI: 10.1073/pnas.202398599. View

Summers J, Smolec J, Snyder R . A virus similar to human hepatitis B virus associated with hepatitis and hepatoma in woodchucks. Proc Natl Acad Sci U S A. 1978; 75(9):4533-7. PMC: 336150. DOI: 10.1073/pnas.75.9.4533. View

10.

Tian Y, Chen W, Ou J . Effects of interferon-α/β on HBV replication determined by viral load. PLoS Pathog. 2011; 7(7):e1002159. PMC: 3145790. DOI: 10.1371/journal.ppat.1002159. View

11.

Zhang G, Budker V, Wolff J . High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther. 1999; 10(10):1735-7. DOI: 10.1089/10430349950017734. View

12.

Lai C, Ratziu V, Yuen M, Poynard T . Viral hepatitis B. Lancet. 2003; 362(9401):2089-94. DOI: 10.1016/S0140-6736(03)15108-2. View

13.

Delaney 4th W, Yang H, Westland C, Das K, Arnold E, Gibbs C . The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro. J Virol. 2003; 77(21):11833-41. PMC: 229343. DOI: 10.1128/jvi.77.21.11833-11841.2003. View

14.

Testut P, Renard C, Terradillos O, Vitvitski-Trepo L, Tekaia F, Degott C . A new hepadnavirus endemic in arctic ground squirrels in Alaska. J Virol. 1996; 70(7):4210-9. PMC: 190351. DOI: 10.1128/JVI.70.7.4210-4219.1996. View

15.

Mason W, Seal G, Summers J . Virus of Pekin ducks with structural and biological relatedness to human hepatitis B virus. J Virol. 1980; 36(3):829-36. PMC: 353710. DOI: 10.1128/JVI.36.3.829-836.1980. View

16.

Locarnini S, Yuen L . Molecular genesis of drug-resistant and vaccine-escape HBV mutants. Antivir Ther. 2010; 15(3 Pt B):451-61. DOI: 10.3851/IMP1499. View

17.

Lai C, Dienstag J, Schiff E, Leung N, Atkins M, Hunt C . Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis. 2003; 36(6):687-96. DOI: 10.1086/368083. View

18.

Chang S, Netter H, Bruns M, Schneider R, Frolich K, Will H . A new avian hepadnavirus infecting snow geese (Anser caerulescens) produces a significant fraction of virions containing single-stranded DNA. Virology. 1999; 262(1):39-54. DOI: 10.1006/viro.1999.9844. View

19.

Yang P, Althage A, Chung J, Maier H, Wieland S, Isogawa M . Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010; 107(2):798-802. PMC: 2818933. DOI: 10.1073/pnas.0913498107. View

20.

Lanford R, Chavez D, Brasky K, Burns 3rd R, Rico-Hesse R . Isolation of a hepadnavirus from the woolly monkey, a New World primate. Proc Natl Acad Sci U S A. 1998; 95(10):5757-61. PMC: 20452. DOI: 10.1073/pnas.95.10.5757. View